Journal of Thrombosis and Circulation Open Access

Bergantin et al., J Thrombo Cir 2017, 3:3
DOI: 10.4172/2572-9462.1000e108

Editorial OMICS International

Potential Cardioprotective Effects of Orlistat for Treatment of Myocardial Infarction

Francisco Sandro Menezes-Rodrigues[1], José Gustavo Padrão Tavares[1], Erisvaldo Amarante de Araújo[1], Luciana de Paula[2], Paolo Ruggero Errante[1], Afonso Caricati-Neto[1] and Leandro Bueno Bergantin[1*]

[1]Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo (UNIFESP), São Paulo-SP, Brazil

[2]Laborvisa–Laboratório de Análises Clínicas, São Paulo-SP, Brazil

[*]**Corresponding author:** Leandro Bueno Bergantin, Ph.D. Laboratory of Autonomic and Cardiovascular Pharmacology, Department of Pharmacology-Escola Paulista de Medicina (EPM), Universida Federal de São Paulo (UNIFESP), Brazil, Tel: 55 11 5576-4973; E-mail: leanbio39@yahoo.com.br

Received date: July 13, 2017; **Accepted date:** July 21, 2017; **Published date:** July 28, 2017

Copyright: © 2017 Bergantin LB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editorial

Acute myocardial infarction (AMI) is characterized by ischemic lesions that severely compromise cardiac structure and function, and even the survival of mammals. The ischemic cardiac diseases (ICD) are related to million deaths per year in the world [1,2]. Although convencional therapy is based on the cardiac reperfusion (R), this procedure increases cardiac damage caused by ischemia (I), and severe arrhythmias (e.g. ventricular arrhythmias and atrio-ventricular blockade) [2-5]. Several reports have demonstrated that cardiac arrhythmias caused by myocardial ischemia and reperfusion (I/R) could be originated from bioenergetic, and electrochemical, imbalance triggered mainly by decrease of ATP synthesis by mitochondria, and cytosolic Ca^{2+} overload in cardiomyocytes [2-5]. This Ca^{2+} overload is massively worsed by the increase of Ca^{2+} influx through L-type voltage-activated Ca^{2+} channels (VACC) caused by continuous membrane depolarization of cardiomyocytes during cardiac I/R [2-5]. In addition, cytosolic Ca^{2+} overload promotes accumulated Ca^{2+} in the mitochondrial matrix via increase of Ca^{2+} influx through mitochondrial uniporter, leading to mitochondrial bioenergetic collapse, and excessive production of free radical, which compromises the structure and function of mitochondria, and other cytoplasmic organelles [2-5]. These cellular mechanisms importantly contribute for developing arrhythmias, and death in AMI patients. Despite continuous advances in AMI treatment, a high ratio of patients dies suddenly in the early hours before arriving at the hospital [6-9]. Most of these early deaths are due to complex ventricular arrhythmias (VA) and atrio-ventricular blockade (AVB) [6-9]. Surprisingly, there is still lack of knowledge about the exact events of these early malignant arrhythmias, and their cellular and molecular mechanisms. Due to involvement of intracellular Ca^{2+} overload in cardiac arrhythmias caused by myocardial I/R, the use of pharmaceuticals that reduce this Ca2+ overload represents an alternative pharmacological approach to the treatment of ischemic cardiac diseases in humans, including AMI. Nonetheless, the cardiac reperfusion (R) continues to be the therapy more used to treat ICD [6-9]. Among the various risk factors for persuing cardiac I/R, we can highlight obesity; this disease has worldwide importance, and it is intrinsically related to cardiovascular diseases (e.g. atherosclerosis and thrombosis). Therefore, there is an incessant and required worldwide research for drugs that effectively act in the treatment of obesity. This is a metabolic disease that arises from biochemical, hormonal and energetic disorders [10,11]. Several drugs are used for the pharmacotherapy of obesity-FDA approved pharmacological monotherapy options-including orlistat (ORL, pancreatic lipase inhibitor) [12,13]. Therefore, our group decided to evaluate potential cardioprotective effects of the agents used in the pharmacotherapy (such as ORL) of dyslipidemia in normotensive rats-treated with ORL for ten days-and submitted to the model of in vivo cardiac I/R developed by our group [14]. The cardioprotection was analyzed by evaluation of the electrophysiological parameters through the electrocardiogram analysis (arrhythmias), and serum concentration biochemical markers of cardiac lesion produced in response to the cardiac I/R protocol (creatine kinase (CK)), low-density lipoprotein cholesterol (LDL-C) and lethality. We observed that the treatment with ORL could decrease the lethality, the serum levels of CK and LDL-C compared to control groups, indicating cardioprotective effects of the ORL. These results suggest that ORL produced cardioprotective effects against cardiac damage caused by cardiac I/R.

Acknowledgments

Research supported by CNPq, FAPESP and CAPES.

References

1. Nag T, Ghosh A (2013) Cardiovascular disease risk factors in Asian Indian population: A systematic review. J Cardiovasc Dis Res 4: 222-228.
2. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. (2015) Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation 132: 1667-1678.
3. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ (2006) Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 48: 1527-537.
4. Pantazi E, Bejaoui M, Folch-Puy E, Adam R, Roselló-Catafau J (2016) Advances in treatment strategies for ischemia reperfusion injury. Expert Opin Pharmacother 8: 1-11.
5. Frank A, Bonney M, Bonney S, Weitzel L, Koeppen M, et al. (2012) Myocardial ischemia reperfusion injury: From basic science to clinical bedside. Semin Cardiothorac Vasc Anesth 16: 123-132.
6. Chen Y, Shao DB, Zhang FX, Zhang J, Yuan W, et al. (2013) Establishment and evaluation of a swine model of acute myocardial infarction and reperfusion-ventricular fibrillation-cardiac arrest using the interventional technique. J Chin Med Assoc 76: 491-496.
7. Xie LH, Weiss JN (2009) Arrhythmogenic consequences of intracellular calcium waves. Am J Physio Heart Circulation Physiology 297: H997-H1002.
8. Zheng Y, Gardner SE, Clarke MC (2011) Cell death, damage-associated molecular patterns, and sterile inflammation in cardiovascular disease. Arterioscler Thromb Vasc Biol 31: 2781-2786.
9. Pokorney SD, Al-Khatib SM (2015) Management of pace terminated ventricular arrhythmias. Card Electrophysiol Clin 7: 497-513.
10. Kim S (2016) Drugs to treat obesity: Do they work? Postgrad Med J 92: 401-406.

11. Narayanaswami V, Dwoskin LP (2016) Obesity: Current and potential pharmacotherapeutics and targets. Pharmacol Ther 30194-30192.
12. Fako VE, Zhang JT, Liu JY (2014) Mechanism of orlistat hydrolysis by the thioesterase of human Fatty acid synthase. ACS Catal 4: 3444-3453.
13. Halpern B, Halpern A (2015) Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications. Expert Opin Drug Saf 14: 305-315.
14. Tavares JG, Vasques ER, Arida RM, Cavalheiro EA, Cabral FR, et al. (2015) Epilepsy-induced electrocardiographic alterations following cardiac ischemia and reperfusion in rats. Braz J Med Biol Res 48: 140-145.